Openbookopenbook
Equity
StockUS listing USBMYNYSEHealthcareDividend King

Bristol-Myers Squibb Company(BMY) Stock Analysis | Healthcare

USD --+0.00%
Reward52Moderate
Risk22Low
75%Data
Strong 19% profit margin · 4.2% dividend yield
USD —+0.00 (+0.00%) Previous close · NYSE
Market cap 120.77Bn
Reward Ratingⓘ52 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ22 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BMY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

AI Brief Pro

The brief on Bristol-Myers Squibb Company

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 120.77B, and a P/E ratio of 13.0x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (52)

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

GLAXFLarge Cap / 118B market cap
GSK plc
Compare
SNYNFLarge Cap / 117B market cap
Sanofi
Compare
CHGCYLarge Cap / 109B market cap
Chugai Pharmaceutical Co Ltd ADR
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
Market Cap120.77B
P/E Ratio13.022
Dividend Yield4.21%
Beta0.184
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
8 disclosures without share count

Openbook research

Articles mentioning BMY

1
Latest researchBrowse all research
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.